HRTIS — Herantis Pharma Oyj Balance Sheet
0.000.00%
- €33.37m
- €33.42m
Annual balance sheet for Herantis Pharma Oyj, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | FAS | FAS | FAS | FAS | FAS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 13.3 | 7.42 | 5.99 | 6.49 | 2.13 |
Net Total Receivables | 0.174 | 0.118 | 0.198 | 0.238 | 0.208 |
Prepaid Expenses | |||||
Total Current Assets | 13.5 | 7.6 | 6.23 | 6.75 | 2.57 |
Net Property, Plant And Equipment | 0 | 0 | 0 | — | — |
Net Intangible Assets | |||||
Total Assets | 16.4 | 7.76 | 6.23 | 6.75 | 2.57 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.89 | 2.61 | 1.9 | 1.99 | 0.634 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 8.83 | 8.9 | 6.29 | 2.02 | 2.81 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 7.59 | -1.14 | -0.06 | 4.73 | -0.243 |
Total Liabilities & Shareholders' Equity | 16.4 | 7.76 | 6.23 | 6.75 | 2.57 |
Total Common Shares Outstanding |